Phase III obesity data show Novo’s semaglutide nearing threshold to replace gastric bypass surgery

Novo announced Phase III data on Wednesday that sets up semaglutide to replace its Saxenda liraglutide as an obesity treatment, and brings the company to the brink of providing a therapeutic alternative to gastric bypass surgery.

Subcutaneous semaglutide, which Novo Nordisk

Read the full 400 word article

How to gain access

Continue reading with a
two-week free trial.